Patent(s) and the Corresponding Patented Drug(s) |
Top |
World Intellectual Property Organization (WIPO) |
Patent ID |
WO2015155738 |
Title |
Use of Gsk-3 Inhibitors or Activators Which Modulate Pd-1 or T-Bet Expression To Modulate T Cell Immunity. |
Abstract |
The present application generally relates to the discovery that glycogen synthase kinase 3 (GSK-3) is an upstream signalling molecule that controls PD-1 transcription and Tbet expression by immune cells and in particular T-cells. Based on this discovery, and in view of the known immunosuppressive effect of PD-1 on immunity and the promoting effect of Tbet on T cell immunity, the present invention relates to the use of GSK-3 inhibitors to promote immunity, including cytotoxic T cell immunity in subjects in need thereof, especially subjects with chronic conditions wherein inhibiting PD-1 expression and/or blockade or Tbet upregulation is therapeutically desirable such as cancer and infectious conditions. Further, based on this discovery the present invention relates to the use of compounds which promote GSK-3 expression or activity to suppress immunity, especially aberrant T cell immunity in subjects in need thereof, e.g., subjects with chronic conditions wherein PD-1 upregulation or Tbet down regulation is therapeutically desirable such as allergic, autoimmune or inflammatory conditions. Also, screening methods for identifying immune agonists and antagonists, especially antibodies, are provided. |
Applicant(s) |
Rudd, Christopher |
Representative Drug(s) |
D0J6UW |
Drug Info
|
N.A. |
Click to Show More |
[1] |
2
|
D0QW6B
|
Drug Info
|
N.A.
|
[1] |
Patent ID |
WO2013182519 |
Title |
Combination of Lysosomotropic or Autophagy Modulating Agents and A Gsk-3 Inhibitor for Treatment of Cancer. |
Abstract |
The invention relates to combinations oflysosomotropic agent or agents modulating autophagy, such as chloroquine, 3-methyladenine or bafilomycin A1, and a GSK-3 inhibitor, such as (2'Z,3'E)-6-bromoindirubin-3'-acetoxime, TDZD-8 or L803-mts. These compositions are useful in the treatment of cancer, proliferative inflammatory diseases, degenerative diseases and some infectious diseases, preferably cancer. The tumor cell survival is particularly dependent on proper endoplasmic reticulumf unction. |
Applicant(s) |
Universitaet Basel |
Representative Drug(s) |
D03SNE |
Drug Info
|
N.A. |
Click to Show More |
[1] |
2
|
D06KNK
|
Drug Info
|
N.A.
|
[1] |
Patent ID |
WO2011064549 |
Title |
Composition and Method for Differentiation of Human Embryonic Stem Cells. |
Abstract |
Described are methods for inducing differentiation of a human embryonic stem cell or a population of human embryonic stem cells toward a cell or population of cells characteristic of the definitive endoderm, the method comprising incubating the cell or population of cells with a GSK-3 inhibitor. Also described are methods for inducing differentiation of a cell or population of cells, characteristic of the definitive endoderm, towards a hepatocyte-like cell or a population of hepatocyte-like cells, and methods for inducing differentiation of a human embryonic stem cell or a population of human embryonic stem cells toward a hepatocyte-like cell or a population of hepatocyte-like cells. Further described are cells obtained by the methods and uses thereof in therapy and toxicity screening. |
Applicant(s) |
Stem Cells for Safer Medicines Limited |
Representative Drug(s) |
D0I2RF |
Drug Info
|
N.A. |
Click to Show More |
[1] |
2
|
D0NG2F
|
Drug Info
|
N.A.
|
[1] |
Patent ID |
WO2014050779 |
Title |
Combination of Gsk3 Inhibitor and Anti-Dr5 Antibody. |
Applicant(s) |
Daiichi Sankyo Company, Limited |
Representative Drug(s) |
D0Z1DH |
Drug Info
|
N.A. |
[1] |
Patent ID |
WO2015131788 |
Title |
Treatment of Neurological Conditions. |
Abstract |
Provided are methods of producing a neuronal phenotype in a glial cell or somatic non-neuronal cell. The methods comprise contacting the glial cell or the somatic non-neuronal cell with a composition including small molecules. Also provided are methods for screening for a therapeutic agent for a neurological condition of a subject. |
Applicant(s) |
Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences |
Representative Drug(s) |
D0YK9D |
Drug Info
|
N.A. |
[1] |
Patent ID |
WO2014083132 |
Title |
Maturation of Hepatocyte-Like Cells Derived From Human Pluripotent Stem Cells. |
Abstract |
The present invention relates to directed differentiation and maturation of hepatocyte-like cells. In particular, the present invention relates to exposure of hepatocyte-like cells to an activator of a retinoic acid responsive receptor, such as retinoic acid (RA), optionally in combination with an inhibitor of GSK-3 (Glycogen synthase kinase 3) or activator of Wnt signalling and/or with the overlay of the cells with one or more components characteristic of the mammalian extracellular matrix (matrix overlay).The present invention also relates to exposure of hepatocyte-like cells to an activator of a retinoic acid responsive receptor, such as retinoic acid (RA), optionally in combination with an inhibitor of a cycline dependent kinase (CDK) and/or with the overlay of the cells with one or more components characteristic of the mammalian extracellular matrix (matrix overlay). The hepatocyte-like cells obtained in accordance with the present invention show a phenotype which is more similar to that of primary hepatocytes than previously shown. |
Applicant(s) |
Takara Bio Europe Ab |
Representative Drug(s) |
D00PWQ |
Drug Info
|
N.A. |
[1] |
Patent ID |
WO2014059383 |
Title |
Gsk3 Inhibitors and Methods of Use Thereof. |
Abstract |
The present invention provides compounds of formula I, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting kinase (e.g., GSK3 (e.g., GSK3a or GSK3P) or CK1) activity. The present invention further provides methods of using the compounds described herein for treating kinase-mediated disorders, such as neurological diseases, psychriatic disorders, metabolic disorders, and cancer. I. |
Applicant(s) |
The Broad Institute, Inc |
Representative Drug(s) |
D0FV9Z |
Drug Info
|
N.A. |
[1] |
Patent ID |
WO2014053580 |
Title |
Anticonvulsant Activity of Gsk-3Beta Inhibitors. |
Abstract |
The present invention relates to the anticonvulsant activity of GSK-3gamainhibitors and the use of GSK-3gama inhibitors as agents for the treatment of neurological disorders characterized by seizures such as epilepsy. |
Applicant(s) |
Katholieke Universiteit Leuven |
Representative Drug(s) |
D0I2RF |
Drug Info
|
N.A. |
[1] |
Patent ID |
WO2014003098 |
Title |
Tricyclic Compound. |
Abstract |
To provide a novel compound which inhibits GSK3 and is useful for the treatment of diseases associated with GSK. Provided is a compound represented by genera formula (1) or a salt thereof. (In the formula, R1, R2, R3, R4, X1 and X2 are as defined in the description.). |
Applicant(s) |
Daiichi Sankyo Co Ltd |
Representative Drug(s) |
D0XR7S |
Drug Info
|
N.A. |
[1] |
Patent ID |
WO2013150284 |
Title |
Tolerisation- Inducing Composition. |
Abstract |
The present invention relates to a composition comprising a tolerogenic peptide and a GSK-3 inhibitor and uses thereof. The invention also relates to the use of a GSK-3 inhibitor to accelerate the peptide-mediated shift in secretion profile of lymphocytes from pro-inflammatory to anti-inflammatory cytokines. The GSK-3 inhibitor may be used to enhance antigen-specific immunotherapy. |
Applicant(s) |
University of Bristol |
Representative Drug(s) |
D0YK9D |
Drug Info
|
N.A. |
[1] |
Patent ID |
WO2011116930 |
Title |
Directed Differentiation and Maturation of Pluripotent Cells Into Hepatocyte Like Cells By Modulation of Wnt-Signalling Pathway. |
Abstract |
Provided are improved methods using Glycogen synthase kinase 3 (GSK3) inhibitors by which endodermal cells, notably endodermal cells derived from human pluripotent stem cells (hPS), such as but not limited to hiPS-cells and hES-cells may be differentiated into hepatocyte like cells. The specific modulation of wingless integration gene (WNT)-signalling pathway and use of GSK3 inhibitors achieve direct differentiation and maturation of hepatocytes derived from human pluripotent stem (hPS) cells. GSK-3 inhibitors, when added to the growth medium at certain developmental stages, leads to more mature and functional features for the hepatocyte like cells as well as more pure and homogenous populations of hepatocyte like cells. Provided are also hepatocyte like cells obtained by these methods as well as compositions comprising them. |
Applicant(s) |
Cellartis Ab |
Representative Drug(s) |
D0I2RF |
Drug Info
|
N.A. |
[1] |
United States Patent and Trademark Office (USPTO) |
Patent ID |
US20160058738 |
Title |
Pharmaceutical Composition for Preventing or Treating Ovary Granulosa Cell Tumors Containing Glycogen Synthase Kinase-3 Beta Inhibitor As Active Ingredient, and Functional Health Food Composition. |
Applicant(s) |
Chung-Ang University |
Representative Drug(s) |
D0A3MV |
Drug Info
|
N.A. |
Click to Show More |
[1] |
2
|
D0QW6B
|
Drug Info
|
N.A.
|
[1] |
Patent ID |
US9469618 |
Title |
Thiadiazolidinediones As Gsk-3 Inhibitors. |
Representative Drug(s) |
D02OGA |
Drug Info
|
N.A. |
Click to Show More |
[1] |
2
|
D0CR2E
|
Drug Info
|
N.A.
|
[1] |
3
|
D0QE2H
|
Drug Info
|
N.A.
|
[1] |
Patent ID |
US8697698 |
Title |
Pyrazole Compounds Useful As Protein Kinase Inhibitors. |
Representative Drug(s) |
D03ETN |
Drug Info
|
N.A. |
Click to Show More |
[1] |
2
|
D08CWE
|
Drug Info
|
N.A.
|
[1] |
3
|
D0J9YX
|
Drug Info
|
N.A.
|
[1] |
Patent ID |
US8653088 |
Title |
Compositions Useful As Inhibitors of Protein Kinases. |
Representative Drug(s) |
D03ETN |
Drug Info
|
N.A. |
Click to Show More |
[1] |
2
|
D08CWE
|
Drug Info
|
N.A.
|
[1] |
3
|
D0J9YX
|
Drug Info
|
N.A.
|
[1] |
Patent ID |
US8642598 |
Title |
Heterocyclic Compounds and Their Use As Glycogen Synthase Kinase 3 Inhibitors. |
Representative Drug(s) |
D06ZRL |
Drug Info
|
N.A. |
Click to Show More |
[1] |
2
|
D0RD9V
|
Drug Info
|
N.A.
|
[1] |
Patent ID |
US2015152389 |
Title |
Generation of Cardiomyocytes From Human Pluripotent Stem Cells. |
Representative Drug(s) |
D0I2RF |
Drug Info
|
N.A. |
Click to Show More |
[1] |
2
|
D0YK9D
|
Drug Info
|
N.A.
|
[1] |
Patent ID |
US2012172376 |
Title |
Heterocyclic Compounds and Their Use As Glycogen Synthase Kinase-3 Inhibitors. |
Representative Drug(s) |
D01WAJ |
Drug Info
|
N.A. |
Click to Show More |
[1] |
2
|
D0NO7V
|
Drug Info
|
N.A.
|
[1] |
Patent ID |
US2012077840 |
Title |
Heterocyclic Compounds and Their Use As Glycogen Synthase Kinase-3 Inhibitors. |
Representative Drug(s) |
D01WAJ |
Drug Info
|
N.A. |
Click to Show More |
[1] |
2
|
D0NO7V
|
Drug Info
|
N.A.
|
[1] |
Patent ID |
US08633210 |
Title |
Triazole Compounds Useful As Protein Kinase Inhibitors. |
Representative Drug(s) |
D03ETN |
Drug Info
|
N.A. |
Click to Show More |
[1] |
2
|
D08CWE
|
Drug Info
|
N.A.
|
[1] |
3
|
D0J9YX
|
Drug Info
|
N.A.
|
[1] |
Patent ID |
US20140005184 |
Title |
Spirocyclic Aminoquinolones As Gsk-3 Inhibitors. |
Representative Drug(s) |
D09PGW |
Drug Info
|
EC50 = 3200 nM; IC50 = 36000 nM |
[1] |
Patent ID |
US08686042 |
Title |
Gsk-3 Inhibitors. |
Representative Drug(s) |
D0UZ7I |
Drug Info
|
IC50 = 17100 nM |
[1] |
Patent ID |
US8778936 |
Title |
Pyrazole Compounds That Modulate The Activity of Cdk, Gsk and Aurora Kinases. |
Representative Drug(s) |
D0M9JE |
Drug Info
|
N.A. |
[1] |
Patent ID |
US8648069 |
Title |
5-Substituted Indazoles As Kinase Inhibitors. |
Representative Drug(s) |
D0UL2V |
Drug Info
|
N.A. |
[1] |
Patent ID |
US2005153992 |
Title |
Pyrrolopyrimidine Thion Derivatives. |
Representative Drug(s) |
D0P8RK |
Drug Info
|
N.A. |
[1] |
European Patent Office (EPO) |
Patent ID |
EP2769720 |
Title |
Heterocyclic Gsk-3 Allosteric Modulators. |
Representative Drug(s) |
D04RDR |
Drug Info
|
N.A. |
Click to Show More |
[1] |
2
|
D0A4QD
|
Drug Info
|
N.A.
|
[1] |